Hikma launches generic Ampyra
Hikma Pharmaceuticals has launched dalfampridine extended-release tablets in a 10-mg dosage strength.
The product, which is the generic of Acorda Therapeutics’ Ampyra, is indicated to help improve walking in adult patients with multiple sclerosis as demonstrated by an increase in walking speed.
Ampyra had a market value of roughly $543 million in 2017, Hikma said.
“We are very pleased to be launching dalfampridine extended-release tablets, a life-enhancing medicine for people with multiple sclerosis. This product highlights our ability to successfully litigate patent-protected Paragraph IV products, improving patient access to high-quality, affordable medicines,” Hikma generics division, president Brian Hoffman, said.
The product, which is the generic of Acorda Therapeutics’ Ampyra, is indicated to help improve walking in adult patients with multiple sclerosis as demonstrated by an increase in walking speed.
Ampyra had a market value of roughly $543 million in 2017, Hikma said.
“We are very pleased to be launching dalfampridine extended-release tablets, a life-enhancing medicine for people with multiple sclerosis. This product highlights our ability to successfully litigate patent-protected Paragraph IV products, improving patient access to high-quality, affordable medicines,” Hikma generics division, president Brian Hoffman, said.